+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Profiling and Pathways: Technologies and Global Markets

  • PDF Icon


  • 255 Pages
  • March 2019
  • Region: Global
  • BCC Research
  • ID: 4760627
UP TO OFF until Aug 31st 2033

Report Scope:

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments are needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity, and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays, and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling, and diagnostics.

Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation, and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials, and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis, and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.

The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.

This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development, and discovery). This report also examines recent studies, microRNA detection, and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. The relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software, and services, providing information critical to understanding the business behind this new technology.

The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

The Report Includes:

  • 91 tables
  • An overview of the global market for cancer profiling and pathways
  • Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of products in this market, newly emerging tools, diagnostics and therapeutics, and their impacts on the market
  • Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
  • Identification of important cancer profiling techniques, market shares by types of products on the market, and market shares by the company, as well as types of cancers and biomarkers
  • Coverage of epigenetics, methylation, and miRNA products in development, products in clinical trials and currently marketed, and clinical-stage development products
  • Company profiles of key players in the market

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Scope of Report
  • Intended Audience
  • Methodology
  • Information Sources
  • Analyst’s Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights
  • Cancer Profiling and Pathways

Chapter 3 Overview
  • Introduction
  • Biomarkers
  • Guidelines
  • Screening Tests
  • Early Detection and Diagnosis of Cancer
  • Pathway Profiling
  • Linking Cancer Disease through Pathway Profiling
  • Molecular Profiling
  • Historical Facts
  • Molecular Profiles
  • Cancer Profiling
  • Challenges
  • Clinical Utility of Molecular Profiling
  • Pathological Classification
  • Molecular Profiling Approaches
  • Cancer Profiling: Future Goals

Chapter 4 Current Profiling Techniques
  • Genomics
  • Genomic Profiling
  • Microarrays
  • Comparative Genomic Hybridization (CGH)
  • Key Companies
  • Key Players
  • Microarrays to Clinical Problems
  • Single Nucleotide Polymorphism (SNP)
  • Multi-color FISH
  • Companies
  • DNA Sequencing
  • Emerging DNA Sequencing Technologies
  • High-throughput Sequencing
  • Other Sequencing Technologies
  • Cancer Applications
  • Next-Gen Sequencing
  • Next-Generation Companies
  • Other Methods
  • Patents and Sequencing
  • Summary
  • Next-Generation Sequencing Technologies
  • Next-Generation Sequencing: Future
  • Genomics and Cancer-Some Examples
  • Mutations Predicting Resistance to Targeted Therapies
  • Sequencing and the Clinic
  • Transcriptomic Profiling
  • Microarray-based Gene Expression Profiling
  • Tiling Arrays
  • qRT-PCR
  • Cancer Applications
  • Emerging Microarray Technologies
  • Future

Chapter 5 Epigenomic Profiling
  • Overview and Introduction to the Epigenetics Landscape
  • Cancer Applications
  • DNA Methylation
  • microRNA
  • Epigenetic Changes and Cancer Stem Cells
  • Epigenetic Therapy for Cancer
  • Leading Epigenetic Companies
  • Epigenetics and MicroRNA Profiling-Finding Pathways to Treatment
  • MicroRNAs and Therapeutic Applications in Cancer
  • MicroRNAs as Prognostic and Therapeutic Biomarkers
  • Anti-Cancer Drugs and microRNA Targets
  • Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
  • Diagnostic and Therapeutic microRNA Strategies in Cancer
  • Therapeutic Potential
  • Therapeutic Strategies
  • MicroRNAs in Disease Diagnostics
  • Circulating microRNAs
  • MicroRNA Profiling Methods
  • Clinical microRNA Diagnostics
  • MicroRNAs in Therapeutics
  • MicroRNA Patents and Outlook
  • Future
  • Methylation Markers
  • DNA Methylation, an Epigenetic Process
  • Current Methods and Products
  • Clinical Implications
  • Future Directions
  • Epigenetic Diagnostic Development
  • Epigenetic Drugs
  • HDAC Inhibitors
  • Epigenetic Therapeutic Development
  • Key Players

Chapter 6 Proteomics
  • Proteomics and Protein Profiling
  • Proteomics Protein Profiling Approaches
  • Techniques
  • Applications of Proteomic Techniques in Cancer Research
  • Technologies and Limitations
  • Proteomics and Initiatives
  • Cancer Applications
  • Proteomics in the Treatment of Cancer
  • Clinical Applications of Proteomics
  • Proteomic Approaches in Therapeutic Targets
  • Key Players
  • Proteomics-Based Diagnostic Products
  • Proteomic Research Centers
  • Clinical Trial Using Proteomics Technologies for Personalized Medicine
  • Proteomics and Medicine
  • Proteomics Market

Chapter 7 Glycomics
  • What is Glycomics?
  • Techniques
  • Analytical High-Throughput Technologies
  • Emergence of Glycoarrays
  • Glycoinformatics
  • Biomedical Applications
  • Glycomics’s Relationship with Other “Omics” Technologies
  • Glycomics for Biomarker Discovery
  • Cancer and Glycomics
  • Glycomics-Biomarkers for Ovarian Cancer
  • U.S. Patents on Glycomics

Chapter 8 Metabolomics
  • What is Metabolomics?
  • Metabolome
  • Techniques
  • Detection Methods
  • Metabolomics and Drug Discovery
  • Biomarker Identification

Chapter 9 Bioinformatics, Databases and Pathway Analysis
Chapter 10 Cancer Profiling and Clinical Development
  • Biomarkers
  • Cancer and Biomarkers

Chapter 11 Market
  • Global DNA Diagnostics Market
  • The Cancer Diagnostics Market
  • Cancer Diagnostic Tests
  • The Cancer/Tumor Profiling Market
  • Personalized Medicine
  • Cancer Biomarker Testing Market
  • Genomics Market
  • SNP Genotyping and Analysis Market
  • Microarray/Biochips Market
  • Diagnostic Microarrays
  • DNA Sequencing Market
  • PCR Market
  • Epigenetics and Market
  • miRNA Market
  • Epigenetics and Cancer Market and Future Growth
  • Proteomics in the Pharma Industry
  • Protein Microarrays and Trends
  • The Metabolomics Market
  • Future
  • Conclusion

List of Tables
Summary Table: Global Cancer Profiling Technologies Market, by Type, Through 2023
Table 1: Technical Approaches for Tumor Molecular Profiling
Table 2: Different Tools for Molecular Profiling of Cancer
Table 3: Genomics: Technologies
Table 4: Applications Market
Table 5: Segment Types
Table 6: List of Techniques/Tools for Genomic Profiling
Table 7: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 8: Commonly Used DNA Microarrays
Table 9: Genomic Tests
Table 10: Selected Companies with Microarray Technologies
Table 11: Key Companies
Table 12: Companies with Sequencing Technologies Next-Generation Sequencers
Table 13: Sequencing Patents Awarded
Table 14: Mutations Identified in Cancer
Table 15: Consortium Listed Responsibilities
Table 16: Transcriptomic Techniques
Table 17: miRNA and siRNA-a Comparison
Table 18: Epigenetic Drugs Approved by the U.S. FDA
Table 19: HDAC Inhibitors
Table 20: Selected Epigenetic Companies
Table 21: Currently Used microRNA Techniques
Table 22: MicroRNA Expression in Cancer
Table 23: Epi-miRNAs Regulating Effectors of the Epigenetic Machinery
Table 24: List of Predicted Targets That are Known Genes Affected in Colon Cancer
Table 25: List of Predicted Targets That are Known Genes Affected in Pancreatic Cancer
Table 26: miRNAs Differentially Expressed Between CRC and Normal Colorectal Tissue
Table 27: miRNAs Differentially Expressed Between Normal Colon and Early-Stage Colorectal Cancer (Stages I and II)
Table 28: miRNAs Differentially Expressed in Early- (I and II) Vs Late-Stage (III and IV) Disease
Table 29: Pathways Targeted by CRC miRNAs
Table 30: MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management
Table 31: MicroRNAs (miRs) with Altered Expression in Ovarian Carcinoma
Table 32: MicroRNA-based Therapeutics: Development Status
Table 33: Selected microRNAs in Development and Cancer
Table 34: microRNA Patents
Table 35: Global microRNA Market for Cancer Profiling Technologies, Through 2023
Table 36: Selected Companies for miRNA-Specific Tools and Reagents
Table 37: Intrinsic Classification of Breast Cancer, by Gene Expression Profiles and Cell Surface Hormonal Expression
Table 38: Select Epigenetic-based Diagnostic Companies
Table 39: Selected Methylation Tests for Cancer
Table 40: Global Epigenetics Market for Cancer Profiling Technologies, Through 2023
Table 41: Epigenetic Drugs for Cancer-Approved/Late-Stage Clinical Trials
Table 42: Methylation Markers in Development
Table 43: Selected Companies with Methylation Products
Table 44: Methylation Markers/Tests-Patents
Table 45: Biomarker Identified Using Two-Dimensional Electrophoresis (2-DE)
Table 46: Biomarker Identified using Mass Spectroscopy (MS)
Table 47: Antibody Array Vendors
Table 48: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 49: The Seven Tumor Glycome Laboratories
Table 50: Clinical Trials and Glycomics
Table 51: U.S. Patents on Glycomics
Table 52: Key Predictive Biomarkers for Trastuzumab Therapy
Table 53: Predictive Biomarkers for EGFR TKI Therapies in Lung Cancer
Table 54: Global DNA Diagnostics Market, Through 2023
Table 55: Cancer Profiling Market: Segment Types
Table 56: Global Cancer Profiling Technologies Market, Through 2023
Table 57: Cancer Profiling Market: Applications
Table 58: Cancer Profiling Market: Technologies
Table 59: Global Biomarkers Market, Through 2023
Table 60: Selected Players
Table 61: U.S. Biomarker Cancer Testing Market, Through 2023
Table 62: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 63: Global SNP Genotyping Market, Through 2023
Table 64: Global Biochips Market, Through 2023
Table 65: Microarray Markets
Table 66: Some Major BioChip Companies
Table 67: Microarrays: Modalities
Table 68: Global Diagnostic Microarray Market for Cancer Profiling Technologies, Through 2023
Table 69: Some Commercially Available Cancer Diagnostic Devices Based on Microarray Technology
Table 70: Microarray Technologies: Key Companies and Products
Table 71: Global DNA Microarray Market, Through 2023
Table 72: MicroArray Products
Table 73: Global Next-Generation Sequencing Market, Through 2023
Table 74: The Next-Generation Sequencing (NGS) Market: Platforms
Table 75: Next-Generation Sequencing-Based Target Enrichment Industry Company Platform Method
Table 76: Noninvasive Prenatal Diagnostics Potential Future Competitors
Table 77: Global Polymerase Chain Reaction Market, Through 2023
Table 78: Key PCR Companies
Table 79: Real-Time (QRTPCR) PCR Selected Companies
Table 80: Global Digital (d)PCR and qPCR Market, Through 2023
Table 81: Global Epigenetics Market, Through 2023
Table 82: Epigenetics Arrays and Selected Cancer Profiling Companies
Table 83: Epigenetic Drugs: Approved by the FDA and Commercially Available
Table 84: Epigenetics and Selected Companies
Table 85: Epigenetic Diagnostic Tests
Table 86: Global miRNA Market for Cancer Profiling Technologies, Through 2023
Table 87: miRNA Market Segments
Table 88: Selected Companies with Methylation Products
Table 89: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 90: Selected Companies Offering, Developing or Partnering to Develop Companion Diagnostics
List of Figures
Summary Figure: Global Cancer Profiling Technologies Market, by Type, 2017-2023
Figure 1: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 2: Global microRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 3: Global Epigenetics Market for Cancer Profiling Technologies, 2017-2023
Figure 4: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
Figure 5: Global DNA Diagnostics Market, 2017-2023
Figure 6: Global Biomarkers Market, 2017-2023
Figure 7: U.S. Biomarker Cancer Testing Market, 2017-2023
Figure 8: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 9: Global SNP Genotyping Market, 2017-2023
Figure 10: Global Biochips Market, 2017-2023
Figure 11: Global Diagnostic Microarray Market for Cancer Profiling Technologies, 2017-2023
Figure 12: Global DNA Microarray Market, 2017-2023
Figure 13: Global Next-Generation Sequencing Market, 2017-2023
Figure 14: Global Polymerase Chain Reaction Market, 2017-2023
Figure 15: Global Digital (d)PCR and qPCR Market, 2017-2023
Figure 16: Global Epigenetics Market, 2017-2023
Figure 17: Global miRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 18: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023

Executive Summary

The global healthcare industry is undergoing key developments, advanced point-of-care diagnostics, availability of cost-effective treatment modalities and personalized medicine, which not only offers efficient early stage diagnosis, while also treating cancer conditions in order to reduce the overall healthcare cost and disease burden. This is one technology which has the potential to revolutionize cancer therapeutics and diagnostics in the healthcare sector.

An effective management and administration of targeted therapeutics and monitoring of cancer condition require frequent profiling of patient’s tumor mutations. Currently, the profiling of cancer has become very critical for cancer diagnosis, clinical trials, research and drug development efforts. With the launch of novel and efficacious targeted therapies that are developed and approved, profiling of tumors will become essential for therapy, patient selection, and monitoring.

It is critical to understand the multivariate nature of cancer is and drug response also depends on molecular profiling at genetic, epigenetic and protein levels. Biomarkers, as defined by the National Institutes of Health (NIH), are “characteristics that are objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” A biomarker has to be reliable, measurable, specific and predictive.

Cancer is a highly heterogeneous disease involving dysregulation of multiple pathways regulating many fundamental cell processes such as growth, death, proliferation, differentiation, and migration. Minor differences and subtle feedback nuances such as tumor microenvironments and endocrine feedback loops, often translate into major differences between cancers, and between patients who have the same cancers. These activities of molecular networks that orchestrate metabolic or cytoskeletal processes, or harmonize these by signal transduction, are altered in a complex manner by many genetic mutations in concert with the environmental context. The challenge is to understand these multivariate dysregulations, with respect to both how it arises from diverse genetic mutations and to how it can be treated. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues.

The major causes of cancer are infection and chronic inflammation. In this report, a general overview of the connection between cancer profiling technologies and cancer is provided. A better insight of these connections can yield novel diagnostic, preventive, and therapeutic strategies to reduce the global cancer burden. Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Newer and improved methods for microarray analysis, multiplex PCR and quantitative real-time PCR are integral to deciphering the molecular mechanisms involved in gene function, cancer development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Innovative tools and techniques for sequencing and tumor profiling are growing and may represent excellent opportunities for life science suppliers.